Check out the companies making the biggest moves premarket: McCormick — Shares rose more than 3% after Unilever confirmed it was in talks with the spices maker over a potential transaction to merge Unilever Foods with McCormick. If a deal were to take place, the Unilever news release said, it would involve “an upfront cash component of approximately US$15.7 billion and the majority of the consideration in McCormick equity. Upon completion of the transaction, it is expected that Unilever and its shareholders would hold 65% of the combined company.” Diageo — The spirits giant climbed nearly 3% after an upgrade to buy from hold at Deutsche Bank. The bank said “structural and cyclical headwinds” such as weakness in alcohol sales are already priced into the stock. Amphenol — The maker of system sensors and antennas gained more than 2% following an upgrade to buy from hold at Jefferies. Analysts at the bank pointed to strong order growth and solid margins for the rating change. Big Tech — The group rose alongside the broader market after a report said President Donald Trump is looking to end the Iran war without reopening the Strait of Hormuz. Meta Platforms and Microsoft climbed more than 1% each. Nvidia and Apple advanced 0.9% and 0.6%, respectively. The four names are lower since the conflict began. Nike — Shares of the athletic shoe maker rose 1.3% ahead of the company’s earnings results set to release Tuesday after the close. Apellis Pharmaceuticals – Shares doubled, up 138%, after Biogen announced it will acquire the company for $5.6 billion in cash. Biogen said the deal will enhance its portfolio in immunology and rare disease. Centessa Pharmaceuticals — The drugmaker surged nearly 48% after Eli Lilly said it agreed to buy the company. Lilly said in a press release the acquisition would help advance work Centessa is doing on treating excessive daytime sleepiness and other neurological conditions. Novo Nordisk — Shares slipped 0.3% after the company announced a multimonth subscription plan for its obesity drug Wegovy products. The plan is expected those paying with cash for the drugs money, up to $1,200 on the injection and $600 on the pill per year, as the company looks to compete more with Eli Lilly which dominates the U.S. GLP-1 market. Marvell Technology – Shares jumped 11% after an announcement that Nvidia will be investing $2 billion in the company as part of a strategic partnership. Nvidia said it plans to connect Marvell to its AI factor and radio access network ecosystems. — CNBC’s Sarah Min and Davis Giangiulio contributed reporting.
